SLC5A2 and type 2 diabetes mellitus: Ketoacidosis occurred in 6 participants allocated to empagliflozin (including five participants on insulin, one of whom had type 1 diabetes, and one participant without diabetes) and one allocated to placebo (who was not taking open-label SGLT2 inhibitor).